Drug Price Trends for GVOKE PFS

Average Pharmacy Cost for GVOKE PFS

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
GVOKE PFS 1-PK 1 MG/0.2 ML SYR	72065-0131-11	1604.31708	ML	2026-02-01
GVOKE PFS 2-PK 1 MG/0.2 ML SYR	72065-0131-12	1607.28747	ML	2026-02-01
GVOKE PFS 2-PK 1 MG/0.2 ML SYR	72065-0131-12	1560.50357	ML	2026-01-21

Market Analysis and Price Projections for GVOKE PFS

Last updated: February 13, 2026

Overview of GVOKE PFS

GVOKE PFS (Tablets) is a sterile, injectable glucagon used to treat severe hypoglycemia in diabetic patients. Approved by the FDA and the European Medicines Agency (EMA) in 2023, GVOKE PFS addresses emergency glucagon administration, offering a pre-filled, ready-to-use device that improves usability over traditional reconstitution-based formulations.

Market Landscape

The global emergency treatment market for severe hypoglycemia is valued at approximately $845 million in 2023. The segment includes traditional glucagon kits, nasally administered drugs, and newer autoinjectors.

Key competitors include:

• Lilly's Glucagon Emergency Kit (reconstitution-based)
• Baqsimi (glucose powder nasal spray)
• Gvoke (liquid glucagon prefilled syringes)
• Dasiglucagon (injectable, market-focused on hypo treatments)

Market Penetration and Adoption

GVOKE PFS's convenience and rapid administration are designed to increase usage among caregivers and healthcare providers. Its pre-filled, auto-injector design aims to reduce administration errors and improve patient safety, potentially expanding its adoption in both home and clinical settings.

Initial uptake is projected to be slow due to entrenched usage of existing products. Adoption is expected to accelerate over 12-24 months once providers and patients recognize benefits.

Pricing Structure and Revenue Potential

The pricing of GVOKE PFS significantly influences market penetration. As of 2023, the wholesale acquisition cost (WAC) stands at approximately $300 per prefilled syringe. The actual retail price to consumers or insurers is higher after markup and reimbursement arrangements.

Comparison to competitors:	Product	Price Range (WAC)	Administration Method	Market Status
GVOKE PFS	~$300	Auto-injector, ready-to-use	Approved, initial sales in 2023
Lilly Glucagon	~$250	Reconstitution required	Established, with steady sales since 2019
Baqsimi	~$300	Nasal spray	Approved since 2019, competitive alternative
Dasiglucagon	~$500	Injectable (hospital focus)	Marketed for hypoglycemia treatment

Price Projections (2023–2030)

Projection assumptions:

• A compound annual growth rate (CAGR) of roughly 10% based on increased prevalence of diabetes and hypoglycemia episodes.
• Launch impact tapering after 24 months; steady growth thereafter.
• Price sensitivity and reimbursement policies influence net pricing.

Year	Estimated Revenue	Average Price per Unit	Units Sold (Millions)	Key Factors
2023	$150 million	~$300	0.5	Market entry, initial adoption
2024	$300 million	~$290	1.0	Growing prescribing, insurance coverage
2025	$450 million	~$280	1.6	Increased awareness, distribution expansion
2026	$600 million	~$275	2.2	Expanded healthcare provider adoption
2027	$750 million	~$270	2.8	Competition intensifies, price stabilization
2028	$900 million	~$265	3.4	Market saturation, new indications
2029	$1.05 billion	~$260	4.0	Broader global adoption
2030	$1.2 billion	~$255	4.7	Price stabilization, growth plateau

Note: These figures are forecast estimates based on current market dynamics, patent protections, and competitive landscape evolutions.

Implications for Stakeholders

• Manufacturers: GVOKE PFS has potential for significant revenue share given its convenience and the growing demand for hypoglycemia treatments.
• Healthcare Providers: Increased preference for user-friendly devices influences prescribing behaviors.
• Insurers: Pricing and reimbursement policies will determine coverage and access.
• Patients: Improved safety and ease of use may expand usage beyond emergency settings into routine diabetic management.

Regulatory and Pricing Policy Impact

Reimbursement policies, especially under U.S. Medicare, Medicaid, and private insurers, exert strong influence. The FDA approved GVOKE PFS with indications aligning it with both emergency and outpatient care. Price negotiations and competitive positioning will determine long-term profitability.

Key Takeaways

• GVOKE PFS launched in 2023 targeting the emergency hypoglycemia market, projected to reach $1.2 billion in revenue by 2030.
• Its convenience and safety profile distinguish it from traditional reconstitution glucagon kits, possibly increasing adoption.
• Initial pricing at approximately $300 per unit positions it competitively against existing products but will need to manage reimbursement and market acceptance.
• Growth depends on expanding awareness and clinician prescribing, with market share gaining as older products face obsolescence.
• Market dynamics are subject to regulatory decisions, patent expirations, and competition from alternative delivery methods.

FAQs

1. What factors could affect the future price of GVOKE PFS?
   Market competition, reimbursement negotiations, manufacturing costs, and regulatory changes influence pricing.

2. How does GVOKE PFS compare to nasal glucagon products?
   GVOKE PFS offers easier administration and faster onset, potentially increasing its market share among caregivers and healthcare providers.

3. What is the impact of patent protection on GVOKE PFS pricing?
   Patent exclusivity supports higher initial prices; patent expiration could lead to price reductions and increased competition.

4. Are there indications for GVOKE PFS beyond hypoglycemia emergencies?
   Current approval limits to hypoglycemia episodes. Future indications depend on additional clinical data.

5. How might reimbursement policies affect GVOKE PFS market penetration?
   Favorable coverage and reimbursement at parity with competitors will be critical for widespread adoption.

Citations

[1] IQVIA MarketInsight, 2023.
[2] FDA Approved Drug Labels, 2023.
[3] MarketWatch, "Global Emergency Glucagon Market," 2023.
[4] Healthcare Financial Management Association, Reimbursement Trends, 2023.